To find if the amount of a certain protein called IRK3 are related to the defense system of the body for being overactive in people with severe lung conditions known as ARDS

Not yet recruiting

Conditions: Acute respiratory failure,

Registration Number: CTRI/2025/04/085806

Lead Sponsor: CSIR Institute of Genomics and Integrative Biology IGIB

Brief Summary: Acute Respiratory Distress Syndrome (ARDS) represents a significant cause of morbidity and mortality in critically ill patients.This study will investigate the correlation between cytokine levels (both pro-and anti-inflammatory) in blood and BAL and IRAK3 levels in lung macrophages in ARDS patients. By categorizing patients into sub-phenotypes based on their inflammatory profiles and assessing IRAK3 expression in both alveolar macrophages and peripheral blood monocytes. This study aims to identify potential biomarkers and therapeutic targets for managing ARDS-associated immune suppression and its complications.This study is a cross-sectional, non - interventional investigation conducted on critically ill ARDS patients admitted to the Intensive Care Unit (ICU). 10 ml of blood and 10 ml of BAL sample will be collected from subjects enrolled in the study. Primary outcome of the study is Cytokine Profiling and Immune Phenotypes and Secondary outcome is Elevated IRAK3 Expression in Immune Suppressive Group at the day of onset of ARDS. Future Benefits of the study are establishment of Potential Biomarkers for Infection Risk and Therapeutic Targeting of IRAK3.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 46

Inclusion Criteria

1 Patients aged 18 years or older will be included as ARDS primarily affects adults 2 Diagnosis of ARDS Only patients diagnosed with ARDS according to the Berlin criteria with suspected or documented Pneumonia infection in blood sputum and or BAL culture will be included in the study 3 Consent Patients or their legally authorized representatives must provide informed consent to participate in the study.

Exclusion Criteria

1 Patients receiving corticosteroid treatment 2 Patients with chronic obstructive pulmonary disease asthma ILD Emphysema or IPF 3 Diabetic patients 4 Immunosuppressive Conditions 5 Patients with Platelet count less than 20000 per microlitre and INR less than one and half 6 Patients with lung cancer existing or with history of Tuberculosis 7 Patients who has gone through lung transplant 8 Patients with pulmonary hypertension 9 Patients with Fungal infection.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cytokine Profiling and Immune Phenotypes	The day of Onset of ARDS

Secondary Outcome Measures

Name	Time	Method
Elevated IRAK3 Expression in Immune Suppressive Group	The day of Onset of ARDS

Trial Locations

Locations (1): Medanta The Medicity
🇮🇳
Gurgaon, HARYANA, India
Medanta The Medicity
🇮🇳Gurgaon, HARYANA, India
Dr Deepak Govil
Principal investigator
09818056688
drdeepak_govil@yahoo.co.in